264 related articles for article (PubMed ID: 21795855)
1. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.
Jiang Y; DiVittore NA; Kaiser JM; Shanmugavelandy SS; Fritz JL; Heakal Y; Tagaram HR; Cheng H; Cabot MC; Staveley-O'Carroll KF; Tran MA; Fox TE; Barth BM; Kester M
Cancer Biol Ther; 2011 Oct; 12(7):574-85. PubMed ID: 21795855
[TBL] [Abstract][Full Text] [Related]
2. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.
Wang T; Wei J; Wang N; Ma JL; Hui PP
Biochem Biophys Res Commun; 2015 Jan; 456(3):821-6. PubMed ID: 25498501
[TBL] [Abstract][Full Text] [Related]
3. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
Senkal CE; Ponnusamy S; Rossi MJ; Sundararaj K; Szulc Z; Bielawski J; Bielawska A; Meyer M; Cobanoglu B; Koybasi S; Sinha D; Day TA; Obeid LM; Hannun YA; Ogretmen B
J Pharmacol Exp Ther; 2006 Jun; 317(3):1188-99. PubMed ID: 16510697
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.
Tagaram HR; Divittore NA; Barth BM; Kaiser JM; Avella D; Kimchi ET; Jiang Y; Isom HC; Kester M; Staveley-O'Carroll KF
Gut; 2011 May; 60(5):695-701. PubMed ID: 21193455
[TBL] [Abstract][Full Text] [Related]
5. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Xin Y; Shen XD; Cheng L; Hong DF; Chen B
Cancer Chemother Pharmacol; 2014 Apr; 73(4):711-9. PubMed ID: 24519751
[TBL] [Abstract][Full Text] [Related]
6. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
Modrak DE; Leon E; Goldenberg DM; Gold DV
Mol Cancer Res; 2009 Jun; 7(6):890-6. PubMed ID: 19531570
[TBL] [Abstract][Full Text] [Related]
7. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.
Beckham TH; Lu P; Jones EE; Marrison T; Lewis CS; Cheng JC; Ramshesh VK; Beeson G; Beeson CC; Drake RR; Bielawska A; Bielawski J; Szulc ZM; Ogretmen B; Norris JS; Liu X
J Pharmacol Exp Ther; 2013 Jan; 344(1):167-78. PubMed ID: 23086228
[TBL] [Abstract][Full Text] [Related]
8. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
9. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
11. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
12. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
13. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
14. Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells.
di Bartolomeo S; Spinedi A
Biochem Biophys Res Commun; 2001 Oct; 288(1):269-74. PubMed ID: 11594784
[TBL] [Abstract][Full Text] [Related]
15. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
Gong L; Yang B; Xu M; Cheng B; Tang X; Zheng P; Jing Y; Wu GJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):69-77. PubMed ID: 24190701
[TBL] [Abstract][Full Text] [Related]
18. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
[TBL] [Abstract][Full Text] [Related]
20. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
